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Poster Session-I 69respectively; median number of prior regimens in both groups was 5.
Twelve patients (30%) in group A and 42 patients (69%) in group B
had a prior autologous SCT.
Results: Median follow up in surviving patients was 8.2 years in
group A and 2 years in group B. Reduced-intensity conditioning
(RIC) regimens were used in 15 patients (37%) in group A, and 56
patients (92%) in group B. Cumulative TRM in group A and B
was 57% and 31%, respectively (p 5 0.006). Disease progression
was seen in 15 patients (37.5%) in group A and in 31 patients
(50%) in group B (p 5 0.22). Time to progression from allo SCT
was 10.1 moths, with no significant difference between the 2 groups
(p5 0.85). As shown in Figures 1 and 2, patients in group B had sig-
nificantly longer PFS (7.3 vs. 4.8 months; p5 0.03, log rank test) and
OS (13.1 Months vs. 5.9 months; p5 0.008, log rank test). Grade II-
IV acute GVHD was seen in 21 patients (52%) in group A, and 21
patients (34%) in group B (p 5 0.09). Limited or extensive chronic
GVHD was seen in 15 patients (37%) in group A, and 20 patients
(32%) in group B (p 5 0.67). At the time of this analysis, 3 patients
in group A and 18 in group B were alive, while 2 patients in group A
and 12 in group B were alive and in remission.
Conclusions: Patients transplanted after January 2000 although
older and having failed a prior ASCT had significantly lower
TRM, lower incidence of acute GVHD and significantly longer
PFS and OS.185
HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANS-
PLANTATION FOR MULTIPLE MYELOMA: ACHIEVEMENT OF COMPLETE
REMISSION IS ASSOCIATED WITH IMPROVED SURVIVAL
Kumar, L., Ghosh, J., Ganessan, P., Gupta, A., Hariprasad, R. All India
Institute of Medical Sciences, New Delhi, India
We analyzed results of 108 patients of multiple myeloma who un-
derwent autologous stem cell transplantation (ASCT). Patients’ me-
dian age was 52 years (range, 26 to 68 years), M:F : 78 : 30. High
dosemelphalan (200mg/m2) was used for conditioning. 66 (61%) pa-
tients had evidence of chemo-sensitive disease prior to transplant. Fol-
lowing ASCT 79.6% of patients responded; complete (CR) - 36%,
very good partial response (VGPR) -29.6%, and partial response
(PR) -13.9%.CRratewas higher for patientswith chemo-sensitive dis-
ease; 33/66patients (50.0%) achievedCRcomparedwith7/42 patients
(14.3%) with progressive disease, p\.01. At a median follow up of 70
months , the median overall (OS) and event-free survival (EFS) is 71
and 42months, respectively . Estimated overall and event-free survival
at 60 months is 54.4%6 0.05 %(SE) and 49.3%6 0.05(SE), respec-
tively.Forpatientswithpre-transplantchemo-sensitivediseasemedian
OS (102 vs 38 months ,p\.0003) and EFS (96 vs for 21 month-
s,p\.0002) is significantly higher. Mean OS for patients with CR is
148.99 months (95% CI 116.75–181.23) (median not reached) and
for those with VGPR is 73.81 (95% CI 58.91–88.71) (median not
reached) ,p\0.04. Median OS for patients with PR, stable disease
and thosewithprogressive disease is 39, 24 and11months, respectively
(p\0.0003). Median EFS for patients with CR is 129.9 months (95%
CI 101.3–158.5) and 52.4 months (95% CI 41–63.8) for those with
VGPR ,p\.03. Median EFS for patients with PR, stable and
progressive disease is 20, 15 and 5 months respectively, p\0.0001.
Conclusion : Survival is significantly better for patients with pre-
transplant chemo-sensitive disease and those who achieve complete
remission following transplant.186
BUSULFANANDCYCLOPHOSPHAMIDEHAS SIMILAROUTCOMES TOHIGH
DOSE MELPHALAN AS A PREPARATIVE REGIMEN FOR AUTOLOGOUS
STEMCELL TRANSPLANTATION IN PATIENTSWITHMULTIPLEMYELOMA
Mahindra, A.1, Bolwell, B.1, Rybicki, L.2, Dean, R.1, Pohlman, B.1,
Sobecks, R.1, Andresen, S.1, Sweetenham, J.1, Kalaycio, M.1, Copelan, E.1
1Cleveland Clinic, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
High dose chemotherapy (HDC) with autologous stem cell trans-
plant (ASCT) has been shown to increase the rate of complete re-
sponse and prolong survival in multiple myeloma (MM). We
report a single-institution experience comparing two conditioning
regimens, busulfan (oral dose, 16mg/kg; intravenous dose 12.8mg/kg) and cyclophosphamide (120mg/kg) (BuCy) versus high dosemel-
phalan (200 mg/m2) (HDM). Between January 2000 and March
2008, 152 patients (pts) with MM underwent HDC with ASCT us-
ing either BuCy (n5 117; 73 pts (62%) received oral Bu) or HDM (n
5 35) in sequential cohorts as the preparative regimen. 61 patients
(52%) in the BuCy group and 26 patients (74%) in the HDM group
were male (p 5 0.02). The two groups were otherwise similar with
respect to age, ISS stage, b2 microglobulin, number of prior chemo-
therapy regimens, prior radiation therapy, FEV1 and DLCOc pre
transplantation. In the group receiving BuCy, 81 patients (69%)
are alive with a median follow up of 20.2 months (range, 5.3–97.5).
In the HDMgroup, 31 patients (88%) are alive with a median follow
up of 18.7 months (range, 3.8–55.4). The median relapse free sur-
vival (RFS) for patients receiving the BuCy regimen was 3.3 years
and for patients receiving HDM has not yet been observed (p 5
0.052). The median overall survival (OS) for patients receiving the
BuCy regimen was 6.1 years and for patients receiving HDM has
not been observed. Patients treated with BuCy achieved granulocyte
count .500/mL by day 10 (range, 9–13) whereas patients treated
with HDM recovered by day 13 (range, 10–17) post-transplant
(p\0.001). Patients achieved platelet counts greater than 20,000/
mL at a median of 12 days (range, 8–46) after BuCy and by 13 days
(range, 8–27) after HDM treatment (p 5 0.039). Treatment related
mortality (TRM) was documented in 7 patients (5.9%) in the BuCy
group and 2 patients (5.7%) in the HDM group. Bacteremia was
documented in 19 patients (16%) in the BuCy group and 10 patients
(28%) in the HDM group. BuCy led to faster hematopoietic recov-
ery compared to HDM. RFS, OS and TRM were similar. BuCy and
HDMconfer similar long-term outcomes with comparable toxicities
as conditioning regimens prior to ASCT in patients withMM. Stud-
ies of tandem transplantation might benefit from using busulfan
based regimen in place of a second melphalan-based regimen.187
MAINTENANCE THERAPY WITH LOW DOSE THALIDOMIDE, DEXAMETH-
ASONE, AND CLARITHROMYCIN (BIAXIN) (BLT-D) FOLLOWING AUTOL-
OGOUS TRANSPLANT (ASCT) FOR MULTIPLE MYELOMA (MM)
Holmberg, L.A.1,2, Bensinger, W.I.1,2 1Fred Hutchinson Cancer Research
Center, Seattle, WA; 2University of Washington School of Medicine,
Seattle, WA
Since relapse remains amajor problem after ASCT forMM, inves-
tigators have looked at the role of maintenance therapy post trans-
plant. It is not yet established as to what maintenance regimen is
best nor what is the optimal duration for therapy. M. Coleman et al
(Leukemia and Lymphoma 43: 1777, 2002) pioneered a regimen of
BLT-D to treat non-transplant MM patients, with high CR/PR
rate(93%). Thus, it seemed reasonable to study the regimen of
BLT-D as maintenance therapy after ASCT for MM. Twenty-seven
patients (stage II, n 5 8; stage III, n 5 19 by Durie-Salmon) were
treated. Before ASCT, 52% of patients received Thalidomide; 37%
received . one regimen (range 2–4) prior to chemomobilization of
PBSC. At time of ASCT, 20% of patients were in CR/nCR. All pa-
tients were conditioned with melphalan 200 mg/m2. At 30–120
days after recovery fromacute toxicity ofASCT,patientswere treated
withBiaxin 250mgpobid, dexamethasone 20mgpoweekly andTha-
lidomide beginning dose 50mg po daily forD1–14, then increased to
100mgpodaily. Aspirinwas used forDVTprevention. After one year
of combination therapy, dexamethasone and Biaxin were stopped.
Thalidomidewas continued as long as tolerated until diseaseprogres-
sion. One patient withdrew from therapy to undergo elective 2nd
ASCT.Neuropathywas themost common toxicity; 11 patients(41%)
stopped because of unimproved $ grade 2 neuropathy, median 12
months of therapy (range 6–30), and 7 patients(30%) required dose
reduction of Thalidomide. One patient stopped Thalidomide for
rash. Nine patients(33%) had dose reduction of dexamethasone.
Median time of Thalidomide therapy for all patients is 15 months
(range 3–43). The number of infections included: pneumonia (n 5
3), viral upper respiratory (n 5 2), sinusitis (n 5 1), and bronchitis
(n 5 3). As of 9/08, 22 patients(82%) remain alive, with median
follow-up of 3.54 years (range 1.98–4.19). Five patients have died
due to infection (n 5 1), MM (n 5 3), and complications of 2nd
ASCT (n5 1). Fifteen patients(56%) of 27 remain alive without dis-
ease progression,medianTTPwas 18months (range 3–39). Four pa-
tients remain on therapy at 25–43 months. In summary, BLT-D can
70 Poster Session-Ibe given post ASCT; however, neuropathy is a significant common
toxicity that required patients to stop therapy. Longer follow-up is
needed to determine the duration of benefit of BLT-Dmaintenance.
With a median follow-up of 42.5 months, the majority of patients re-
main alive without evidence of disease progression.188
PERIPHERAL BLOOD CD34 COUNT CAN PREDICT SUCCESSFUL PROGEN-
ITOR CELL MOBILIZATION IN POOR MOBILIZIERS TREATED WITH
PLERIXAFOR AND G-CSF
Micallef, I.N.1, Maurer, M.2, Ansell, S.M.1, Buadi, F.1, Dispenzieri, A.1,
Gastineau, D.A.1, Gertz, M.A.1, Hayman, S.R.1, Hogan, W.J.1,
Inwards, D.J.1, Johnston, P.B.1, Kumar, S.1, Lacy, M.Q.1, Litzow, M.R.1,
Porrata, L.F.1, Winters, J.L.3, Marzolf, M.1, Shaw, T.1, Calandra, G.4
1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN; 3Mayo Clinic,
Rochester, MN; 4Genzyme Transplant, Cambridge, MA
Background:The failure rate for CD341 cell mobilization varies
from 5% in MM to 30% in NHL and HD.
Methods:We report the results of a single center experience with
plerixafor1G-CSF as re-mobilization in patients whom a prior mo-
bilization has failed. Mobilization failure was defined as inability to
collect 2  106 CD341 cells/kg or inability to achieve a peripheral
blood CD341 cells/ml of $10 and not apheresed. Re-mobilization
consisted of G-CSF at 10mcg/kg/day sq on days 1–4 plus plerixafor
240 mcg/kg/day sq on the evening of day 4. Both drugs were contin-
ued daily until a goal of 5  106 CD341 cells/kg was reached or
a maximum of 7 aphereses. Apheresis began on day 5 regardless of
the peripheral blood (pb) CD 341 cells/ml. PB CD341 was corre-
lated to CD341 harvested. In addition, we sought to determine if
there was a pb CD341 count pre or post plerixafor that would pre-
dict for a successful harvest of either 2 or 5 106 CD341 cells/kg.
Results: Baseline demographics were as follows: 54 patients, 25
females: 29 males; 29 NHL, 15 MM, 6 HD and 4 AL amyloidosis.
Median age was 64 years (range 30–76). Prior mobilization was
predominantly G-CSF alone. Median time from prior mobilization
to re-mobilization was 0.7 months (range 0.4–33 months). The me-
dian pb CD341 cells/ml prior to plerixafor was 4.5 (range 0–25)
and 12 hours post plerixaforwas 11.5 (range 0–50).Themedian num-
ber harvestedwas 4.61106CD341 cells/kg (range0.08–9.37). 41%
of patients successfully collected$ 5106 CD341 cells/kg and 74%
collected $ 2 106 CD341 cells/kg. PB CD341 correlated with
CD341 harvested on a daily basis (p \0.0001). PB CD341 pre
and post plerixaforwas able to predict success of collection (see table).
% success % successPB CD341 cells/ml
$2  106 CD341
cells/kg
$5  106
CD341 cells/kgPre-Plerixafor
\5 56% 25%
5–10 100% 64%Post Plerixafor
\5 15% 8%
5–10 83% 8%
.10 97% 69%Conclusion: The combination of plerixafor and G-CSF effec-
tively mobilizes CD341 cells in the majority of pts, in whom a prior
mobilization has failed. PB CD341 remains an important predictor
of CD341 harvested. PB CD341 pre-plerixafor of $5 cells/ ml is
associated with a 100% success rate.189
USE OF SECOND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANS-
PLANTS FOR THE TREATMENT OF MULTIPLE MYELOMA
Harris, P.J., Ririe, D.W. San Antonio Military Medical Center South,
Lackland AFB, TX
Introduction: In patientswith newly diagnosedmultiplemyeloma
who are candidates for autologous stem cell transplant (ASCT), it is
often recommended to proceed straight to ASCT after a response
to initial induction therapy as a way of prolonging progression freesurvival compared to chemotherapy alone. Second (tandem) ASCTs
have been routinely performed in patients with less than a very good
partial response to first transplant, since data has shown improved
survival in this subset of patients. We were interested in reviewing
the number of patients who had received single or tandem ASCTs
formultiplemyeloma, and to evaluate factors influencing thedecision
of whether or not to proceed to a second ASCT.
Methods: This is a single institution retrospective review of pa-
tients who have received an ASCT for multiple myeloma from 1
Jan 2000 until 15 April 2008 at San AntonioMilitaryMedical Center
South in San Antonio, TX. Data was collected regarding patient age,
stage, performance status, cytogenetics, lactate dehydrogenase, beta
-2- microglobulin and albumin levels at diagnosis, treatment given,
number of cells harvested and number and type of transplants
received as well as response to each transplant.
Results: Seventeen of 81 patients (21%)who received oneASCT for
the diagnosis of multiple myeloma went on to receive a second ASCT.
Discussion: Seventy-nine percent of patients at our institution
during the specified times did not receive a tandem ASCT for mul-
tiple myeloma. Patient and disease factors which may have influ-
enced the decision of whether to proceed to a second ASCT are
discussed. Since many patients do not receive the second transplant,
and with the cost of and space required to store unused harvested
cells as well as the time and effort required of patients to collect
enough cells for two transplants, this data may help reduce initial
over collection of hematopoietic stem cells.190
SELECTIVE T-CELL IMMUNOTHERAPY FOR B-CELL LYMPHOMA UNDER
HYPOXIA
Ang, S.O.1, Olivares, S.1, Shpall, E.2, Lee, D.A.1, Champlin, R.E.2,
Yotnda, P.3, Gottschalk, S.M.G.3, Cooper, L.J.N.1 1University of Texas MD
Anderson Cancer Center, Houston, TX; 2University of Texas MD Anderson
Cancer Center, Houston, TX; 3Baylor College of Medicine, Houston, TX
Many tumors harbor chronic and intermittent hypoxic cellular
niches giving a survival advantage to malignant cells including cancer
stem cells. To achieve a successful immunotherapeutic response, T
cellsmust overcome physiological challenges specific to the tumormi-
croenvironment such as hypoxia. To exploit the hypoxic tumormicro-
environment, we introduce a new approach that exploits hypoxia as
a condition for T-cell activation. In addition, this approach may be
used to limit off-target effects to normal cells expressing antigen under
normoxia. We demonstrate that a chimeric antigen receptor (CAR),
which is specific forCD19, expressed onmalignant and normal B cells,
can be conditionally expressed in a strictly oxygen-sensitive manner.
Using the Sleeping Beauty transposon/transposase system, we can
achieve stable, persistent CAR transgene expression from DNA plas-
mids without the expense and complexity of retroviral production.
Cell surface expressionof ourCAR is high at 1%O2 andnot detectable
at 20%O2. This oxygen-sensitive CAR is designed to deactivate when
Tcells circulate out of hypoxic tumormicroenvironments tominimize
deleterious off-target effects in vivo. When supplemented with one or
more survival factors and/or homing receptors, this approach to CAR
expression has the advantage of transforming hypoxia from an adverse
factor to a T-cell triggering mechanism. This is expected to be of
broad interest as investigators implement T-cell immunotherapy to
eliminate tumors from the hypoxic niche aswell as develop approaches
that limit T-cell targeting within desired microenvironments thereby
decreasing the possibility of inadvertent targeting of normal tissues.191
CONTINUED M PROTEIN RESPONSES BEYOND DAY 100 AFTER AUTOLO-
GOUS TRANSPLANTATION FOR MYELOMA: IMPLICATIONS FOR POST
TRANSPLANT STRATEGIES
Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S., Buadi, F.K.,
Dingli, D., Rajkumar, S.V., Litzow, M.R., Gertz, M.A. Mayo Clinic,
Rochester, MN
Background: Patients undergoing autologous stem cell trans-
plantation (SCT) for myeloma usually undergo disease evaluation
approximately 100 days after the SCT. Decisions regarding post
